Growth & profitability
- Revenue has grown 19.9% per year over the past 5 years.
- Operating margin has expanded, at -12.8% in the latest year.
Financial health
- Operating income covered interest expense -5.8× in the latest year.
TVTX Financials Travere Therapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $491M | -$26M | 97.9% | -12.8% | — | — | $93M |
| 2024 | $233M | -$322M | 96.7% | -138.9% | — | — | $59M |
| 2023 | $145M | -$111M | 92.1% | -267.2% | -$281M | — | $58M |
| 2022 | $109M | -$278M | 96.0% | -292.2% | -$186M | — | $62M |
| 2021 | $132M | -$180M | 97.1% | -151.3% | -$20M | — | $166M |
| 2020 | $198M | -$169M | 96.9% | -88.8% | -$50M | — | $85M |
| 2019 | $175M | -$146M | 97.0% | -78.3% | -$58M | — | $62M |
| 2018 | $164M | -$103M | 96.6% | -48.7% | -$26M | — | $103M |
| 2017 | $155M | -$60M | 97.7% | -34.7% | $7M | — | $99M |
| 2016 | $134M | -$48M | 96.6% | -43.6% | -$5M | — | $41M |
| 2015 | — | $117M | — | — | -$1M | — | $38M |
| 2014 | — | -$111M | — | — | — | — | $18M |
| 2013 | — | -$35M | — | — | -$18M | — | $6M |
| 2013 | — | -$56M | — | — | -$13M | — | $13M |
| 2013 | — | -$43M | — | — | -$10M | — | $286514 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $127M | -$37M | 98.5% | -29.0% | — | — | $78M |
| Dec '25 | $130M | $3M | 98.0% | -25.0% | — | — | $93M |
| Sep '25 | $165M | $26M | 99.0% | 15.1% | $14M | — | $111M |
| Jun '25 | $114M | -$13M | 98.7% | -11.1% | — | — | $75M |
| Mar '25 | $82M | -$41M | 94.3% | -52.2% | — | — | $62M |
| Dec '24 | $75M | -$60M | 96.6% | -81.2% | — | — | $59M |
| Sep '24 | $63M | -$55M | 97.4% | -89.3% | -$43M | — | $36M |
| Jun '24 | $54M | -$70M | 96.2% | -125.1% | -$40M | — | $32M |
| Mar '24 | $41M | -$136M | 96.4% | -336.5% | -$119M | — | $43M |
| Dec '23 | $45M | -$90M | 89.9% | -209.1% | -$70M | — | $58M |
| Sep '23 | $37M | $151M | 96.5% | -249.6% | -$59M | — | $144M |
| Jun '23 | $32M | -$86M | 95.5% | -322.9% | -$69M | — | $71M |
| Mar '23 | $31M | -$86M | 86.6% | -315.2% | -$82M | — | $161M |
| Dec '22 | $29M | -$66M | 97.0% | -295.5% | -$55M | — | $62M |
| Sep '22 | $28M | -$70M | 96.0% | -294.2% | -$40M | — | $151M |
| Jun '22 | $29M | -$67M | 92.8% | -274.2% | -$37M | — | $180M |
| Mar '22 | $48M | -$76M | 95.6% | -136.4% | -$55M | — | $257M |
| Dec '21 | $57M | -$52M | 96.7% | -82.4% | -$27M | — | $166M |
| Sep '21 | $68M | -$36M | 97.7% | -46.5% | $32M | — | $150M |
| Jun '21 | $55M | -$39M | 97.0% | -64.7% | $6M | — | $83M |
Valuation over time
How the market has priced TVTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 19.1× (Mar '23) to 11.2× (Jun '26).
P/S
Frequently asked questions
Is TVTX growing its revenue and profit?
Over the past 5 years, Travere Therapeutics, Inc.'s revenue has grown 19.9% per year. These are computed facts, not advice.
How much debt does TVTX have?
As of FY2025, Travere Therapeutics, Inc. reported — of total debt against $93M of cash; operating income covered interest expense -5.8×.
What is TVTX's profit margin?
In FY2025, gross margin was 97.9%, operating margin -12.8%, and net margin -5.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.